State-of-the-Art Lecture: What Are The Most Important Ongoing Clinical Trials In Urologic Oncology Worldwide?
ORLANDO, FL (UroToday.com) - Dr. Crawford presented information on challenges facing clinical trials from SWOG, ECOG and CALGB. Patient accrual for clinical trials is only 2-3%. Innumerable layers of rules and regulations have been created with numerous layers that increase costs and delays.
5 Top Young Clinical Investigators Receive Damon Runyon Cancer Research Foundation Awards
The Damon Runyon Cancer Research Foundation named 5 new Damon Runyon Clinical Investigators at its May 2008 Clinical Investigator Award Committee review. The recipients of this prestigious, three-year award are outstanding early career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation's leading scientists and clinicians.
State-of-the-Art Lecture: Aptomers Of Nanotechnology - Reported From The Annual Meeting Of The American Urological Association
ORLANDO, FL (UroToday.com) - Dr. Omid Farokhzad from Harvard addressed nanotechnology. Nanotechnology is the assembly of particles
AAD, MLB And MLB Players Association Play Sun Smart To Strike Out Skin Cancer
Major League Baseball (MLB) and the Major League Baseball Players Association (MLBPA) are teaming up with the American Academy of Dermatology (Academy) this summer through the Play Sun SmartTM program to educate players and fans about skin cancer. The many hours spent in the midday sun playing baseball or cheering for their favorite team puts both players and fans at risk for skin cancer, a potentially life-threatening condition that affects 1 in 5 Americans.
Oncolin Therapeutics Announces Its Cancer Technology Will Be Presented At The 20th EORTC-NCI-AACR Symposium
Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) will be presenting its lead cancer technology at this prestigious symposium in Geneva Switzerland in October 2008.
CB1400, Patented By Canopus BioPharma, Prevents Tumor Growth And Enhances The Anti-Tumor Effects Of Cisplatin And Cetuximab Erbitux
Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models.
Merck Applies To Extend Use Of Erbitux For 1st-Line Head And Neck Cancer In Europe
Merck KGaA announced that it has submitted an application to the European Medicines Agency (EMEA) to broaden the use of the targeted therapy Erbitux (cetuximab) to include 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Indiana University Simon Cancer Center Priority: Reduce Cancer Incidences, Mortality Among State's Diverse Populations
Cancer knows no boundaries. It strikes men and women. Rich and poor. Young and old. One difference, however, is the frequency and severity of the disease when diagnosed. Too often minority groups and rural area populations face higher cancer incidences and higher mortality rates.
Melanoma Is On The Rise In Women
Over the past few decades, the incidence of melanoma, the deadliest from of skin cancer, has increased. Melanoma has become the most common cancer in women between the ages of 25 and 29. Overall, skin cancer is the most common cancer among men and women in the United States.
Obesity Surgery May Reduce Cancer Risk
Two studies from Canada and Brazil announced at conferences earlier this week suggest that bariatric or weight-loss surgery to control obesity may also cut cancer risk.